Literature DB >> 27330105

Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.

Scott M Haake1, Jamie D Weyandt1, W Kimryn Rathmell2.   

Abstract

The renal cell carcinomas (RCC), clear cell, papillary, and chromophobe, have recently undergone an unmatched genomic characterization by The Cancer Genome Atlas. This analysis has revealed new insights into each of these malignancies and underscores the unique biology of clear cell, papillary, and chromophobe RCC. Themes that have emerged include distinct mechanisms of metabolic dysregulation and common mutations in chromatin modifier genes. Importantly, the papillary RCC classification encompasses a heterogeneous group of diseases, each with highly distinct genetic and molecular features. In conclusion, this review summarizes RCCs that represent a diverse set of malignancies, each with novel biologic programs that define new paradigms for cancer biology. Mol Cancer Res; 14(7); 589-98. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27330105      PMCID: PMC4955752          DOI: 10.1158/1541-7786.MCR-16-0115

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  76 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

Review 2.  Effects of hypoxia and HIFs on cancer metabolism.

Authors:  Vera Mucaj; Jessica E S Shay; M Celeste Simon
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

5.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

6.  Disruption of tubular Flcn expression as a mouse model for renal tumor induction.

Authors:  Jindong Chen; Dachuan Huang; Isabelle Rubera; Kunihiko Futami; Pengfei Wang; Peter Zickert; Sok-Kean Khoo; Karl Dykema; Ping Zhao; David Petillo; Brian Cao; Zhongfa Zhang; Shuhui Si; Susan R Schoen; Ximing J Yang; Ming Zhou; Guang-Qian Xiao; Guan Wu; Magnus Nordenskjöld; Michel Tauc; Bart O Williams; Kyle A Furge; Bin Tean Teh
Journal:  Kidney Int       Date:  2015-06-17       Impact factor: 10.612

7.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

8.  Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas.

Authors:  A Kovacs; S Storkel; W Thoenes; G Kovacs
Journal:  J Pathol       Date:  1992-07       Impact factor: 7.996

9.  CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.

Authors:  Aikseng Ooi; Karl Dykema; Asif Ansari; David Petillo; John Snider; Richard Kahnoski; John Anema; David Craig; John Carpten; Bin-Tean Teh; Kyle A Furge
Journal:  Cancer Res       Date:  2013-01-30       Impact factor: 12.701

10.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.

Authors:  Tatsuhiro Shibata; Tsutomu Ohta; Kit I Tong; Akiko Kokubu; Reiko Odogawa; Koji Tsuta; Hisao Asamura; Masayuki Yamamoto; Setsuo Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

View more
  9 in total

Review 1.  Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.

Authors:  Jamie D Weyandt; Craig B Thompson; Amato J Giaccia; W Kimryn Rathmell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

2.  A New Chromatin-Cytoskeleton Link in Cancer.

Authors:  Amato J Giaccia
Journal:  Mol Cancer Res       Date:  2016-08-15       Impact factor: 5.852

3.  Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.

Authors:  Ho Won Kang; Xuan Mei Piao; Hee Youn Lee; Kyeong Kim; Sung Pil Seo; Yun Sok Ha; Yeong Uk Kim; Won Tae Kim; Yong June Kim; Sang Cheol Lee; Wun Jae Kim; Eun Young Shin; Eung Gook Kim; Seok Joong Yun
Journal:  Investig Clin Urol       Date:  2021-05-17

Review 4.  Metabolic reprogramming in renal cancer: Events of a metabolic disease.

Authors:  Samik Chakraborty; Murugabaskar Balan; Akash Sabarwal; Toni K Choueiri; Soumitro Pal
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-05-06       Impact factor: 11.414

5.  Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation.

Authors:  Ayham Al Ahmad; Vanessa Paffrath; Rosanna Clima; Jonas Felix Busch; Anja Rabien; Ergin Kilic; Sonia Villegas; Bernd Timmermann; Marcella Attimonelli; Klaus Jung; David Meierhofer
Journal:  Cancers (Basel)       Date:  2019-09-03       Impact factor: 6.639

Review 6.  Modeling clear cell renal cell carcinoma and therapeutic implications.

Authors:  Melissa M Wolf; W Kimryn Rathmell; Kathryn E Beckermann
Journal:  Oncogene       Date:  2020-03-02       Impact factor: 9.867

Review 7.  Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics.

Authors:  Daniel D Shapiro; Maria Virumbrales-Muñoz; David J Beebe; E Jason Abel
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

Review 8.  Papillary renal cell carcinoma: current and controversial issues.

Authors:  Silvia Angori; João Lobo; Holger Moch
Journal:  Curr Opin Urol       Date:  2022-06-09       Impact factor: 2.808

Review 9.  Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.

Authors:  W Kimryn Rathmell; Jeffrey C Rathmell; W Marston Linehan
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.